The V-Go Insulin Delivery Device Used In Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control

Rosenfeld, Cheryl R.; Bohannon, Nancy J. V.; Bode, Bruce W.; Kelman, Adam S.; Mintz, Shari N.; Schorr, Alan B.; Sandberg, Marc I.; Nambi, Sridhar S.; Agarwala, Sumon K.; Leichter, Steven B.; Larrabee, Bart; Shi, Lei; Strange, Poul

doi:10.4158/ep11362.or

Cited by 23 publications

(27 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient impressions of V-Go were generally high across all questions surveyed in this study, which is consistent with previous treatment satisfaction surveys [9,16]. V-Go ease of use compared to previous therapy received the highest rating (8.7 out of 10), which is significant considering that regimen complexity and patient satisfaction can both impact patient compliance, which is critical to improving glycemic control [19].…”

Section: Discussionsupporting

confidence: 87%

“…After 24 h, the patient presses the needle release button, which retracts the needle back into the V-Go, allowing the removal and disposal of the device used before a new V-Go is applied and initiated [7]. Patients have reported the V-Go device to be discreet and easy to use, and the basal and bolus capability of the device eliminates the need for multiple injections, all of which may help improve patient compliance with insulin therapy [8,9]. Evidence has supported an improvement in glycemic control with V-Go [9][10][11][12][13][14][15][16][17]; however, prospective data are lacking, and further evidence is warranted to understand the impact of V-Go across a wide range of patients.…”

Section: Key Pointsmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study

Grunberger

Rosenfeld

Bode

et al. 2019

Drugs - Real World Outcomes

Self Cite

View full text Add to dashboard Cite

Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in patients switched to V-Go in a real-world setting. The primary objective was to compare change in mean hemoglobin A1c (HbA1c) from baseline to the end of V-Go use. Methods This prospective, open-label, multicenter study recruited patients with type 2 diabetes (T2D) and suboptimal glycemic control (HbA1c ≥ 7%) across 28 centers. Efficacy analyses were conducted for all patients with a post-baseline HbA1c and results stratified based on prior antihyperglycemic medication therapies. Insulin dosing was at the discretion of the health care provider and the protocol did not mandate glycemic targets. Treatment satisfaction surveys were utilized to gain patient feedback on the use of V-Go. Results One hundred eighty-eight patients were enrolled in the study, among whom 140 patients had a valid post-baseline HbA1c and were included in the primary efficacy analysis. Use of V-Go resulted in a change of − 0.64%; (P = 0.003) in HbA1c from baseline, and in those prescribed insulin, the total daily dose of insulin was decreased by 12 units/day (P < 0.0001). Twenty-two patients (12%) reported hypoglycemic events (≤ 70 mg/dL), with an event rate of 1.51 events/ patient/year. Conclusion In a T2D population with suboptimal HbA1c, initiating V-Go therapy in a real-world setting significantly improved glycemic control and led to significant insulin dose reductions. ClinicalTrial.gov registry identifier: NCT01326598.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Key Pointsmentioning

confidence: 99%

Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study

Grunberger

Rosenfeld

Bode

et al. 2019

Drugs - Real World Outcomes

Self Cite

View full text Add to dashboard Cite

show abstract

“…2 Generally, patient satisfaction with this technology was high, as reported in this study (average scores 8.7/10 with 10 being the most positive for V-Go).…”

supporting

confidence: 68%

Where to Go Now With V-Go?

Thompson

Cook

2015

J Diabetes Sci Technol

View full text Add to dashboard Cite

V-Go™ is a mechanical continuous insulin delivery device releasing a basal amount of rapid acting insulin that also allows the user the ability to deliver discrete meal time or correction doses. This analysis reviews available published literature on the technology, and discusses a recent article comparing the V-Go system with multiple daily insulin injection therapy. Finally, suggestions for future studies are provided.

show abstract

“…Alternative delivery options are becoming available that may increase adherence. Delivering insulin to mimic normal physiology through a more convenient device may help reduce HbA 1c levels to within recommended ranges 1,15,20. The results of this retrospective analysis showed that among patients with at least one laboratory test for HbA 1c , half had glycemic levels above the recommended goal.…”

Section: Discussionmentioning

confidence: 95%

“…The device is mechanical, not electronic, providing convenient and simple physiologic basal bolus delivery of insulin. The efficacy of the device has been previously demonstrated in small-scale settings;15,20 however, prospective real-world effectiveness data are limited.…”

Section: Introductionmentioning

confidence: 99%

Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device

Grabner¹,

Chen²,

Nguyen³

et al. 2013

CEOR

View full text Add to dashboard Cite

ObjectiveTo inform the design and assess the feasibility of a prospective effectiveness study evaluating an insulin delivery device for patients with diabetes mellitus to be conducted within the membership of a large US commercial insurer.MethodsProviders who issued ≥1 insulin prescription between January 1, 2011 and September 30, 2011 were selected from administrative claims contained in the HealthCore Integrated Research DatabaseSM. Adult diabetes patients with visits to these providers were identified. Providers were dichotomized into high- (HVPs) and low-volume providers (LVPs) based on median number of diabetes patients per provider.ResultsWe identified 15,349 HVPs and 15,313 LVPs (median number of patients = 14). Most HVPs were located in the Midwest (6,291 [41.0%]) and South (5,092 [33.2%]), while LVPs were evenly distributed across regions. Over 80% (12,769) of HVPs practiced family or internal medicine; 6.4% (989) were endocrinologists. HVPs prescribed insulin to an average of 25% of patients. Patients of HVPs (522,527) had similar characteristics as patients of LVPs (80,669), except for geographical dispersion, which followed that of providers. Approximately 65% of patients were aged 21–64 years and 97% had type 2 diabetes. Among patients with ≥1 available HbA1C result during 2011 (103,992), 48.3% (50,193) had an average HbA1C ≥7.0%. Among patients initiating insulin, 79.6% (22,205) had an average HbA1C ≥7.0%.ConclusionThe observed provider and patient populations support the feasibility of the prospective study. Sampling of patients from HVPs is efficient while minimizing bias as patient characteristics are similar to those from LVPs. The study also highlights unmet needs for improved glycemic control since approximately half of patients with diabetes are not on goal.

show abstract

The V-Go Insulin Delivery Device Used In Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control

Cited by 23 publications

References 7 publications

Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study

Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study

Where to Go Now With V-Go?

Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device

Contact Info

Product

Resources

About